Class-wide label change for opioids; positive results for oral GLP-1; migraine prevention therapy approved for children; FDA removes restriction on Ixchiq for older adults; Modeyso approved for rare ...

In the most severe erosive esophagitis patients (LA grade C or D), tegoprazan 100mg was found to be statistically superior to lansoprazole for maintenance of healing at 24 weeks. Noninferiority vs ...

The randomized, double-blind, CONVOKE trial evaluated the safety and efficacy of CT-155, a PDT that provides interactive psychosocial intervention techniques via a smartphone app.

Findings from key secondary endpoints showed 59.6% of patients taking orforglipron 36mg (highest dose) achieved a reduction in body weight of 10% or greater vs 8.6% of patients receiving placebo; ...

As part of a postmarketing requirement, Valneva will be initiating a study to assess the risk of severe chikungunya-like adverse reactions following administration of Ixchiq.

The Food and Drug Administration (FDA) has granted accelerated approval to Modeyso ™ (dordaviprone), a protease activator, for the treatment of adult and pediatric patients aged 1 year and older with ...

No significant increases seen in rate of hospital contacts for any of 29 adverse events in 28-day risk period after vaccination.

Cognitive functional therapy, with or without biofeedback, more effective than usual care for chronic disabling low back pain.

HealthDay News — Canagliflozin is associated with a clinically meaningful reduction in hemoglobin A1c (HbA1c) for children and adolescents with type 2 diabetes mellitus (T2DM), according to a study ...

Watchful waiting extended as initial management strategy for all patients with uncomplicated acute bacterial rhinosinusitis ...

Stronger differential effect for CPAP seen for those without excessive sleepiness, without increased blood pressure.